Skip to main content

ChronoScale Holdings Corp

corporate_fare Company Profile

ChronoScale Holdings Corp

CHRN·NASDAQ·Technology·CIK 0001549084

Founded in 2005, we are a Nevada corporation that designs, develops, and markets exoskeleton products that augment human strength, endurance, and mobility. Our primary end market is healthcare, where our technology serves people with physical disabilities or impairments in both physical rehabilitation and mobility. The majority of our sales come from our Enterprise Health products, which include sales of products and services related to neurorehabilitation in clinical settings. We also offer products and services from our Personal Health market to individual users. Our product lineup includes EksoNR, a wearable robotic exoskeleton for rehabilitation settings. It assists individuals recovering from acute and chronic conditions, providing adjustable assistance to the wearer's legs to promote proper gait, active engagement, and higher dosage. EksoNR is cleared by the FDA for use in clinical settings with individuals with spinal cord injury (SCI), acquired brain injury (ABI)—including stroke and traumatic brain injuries (TBI)—and multiple sclerosis (MS). We also offer Ekso Indego Therapy, a modular, adjustable, lightweight, lower-limb powered exoskeleton for rehabilitation and wellness applications. It is cleared by the FDA for use with individuals with stroke or SCI. Ekso Indego Personal is a lightweight powered lower limb orthosis that enables people with mobility impairments to walk independently. It is cleared by the FDA for use with individuals with SCI levels from T3 to L5 in community or home settings. Additionally, we provide Ekso Nomad, a power Knee Ankle Foot Orthosis (KAFO).

ChronoScale Holdings Corp (NASDAQ:CHRN) is a publicly traded company in the Technology sector. Wiseek monitors CHRN SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.

Recent high-impact activity:

  • ChronoScale Files Cloud Business Financials, Alleviating Going Concern Doubt Post-Merger
  • ChronoScale Secures $100M Non-Dilutive Line of Credit from Parent Applied Digital
  • ChronoScale to Divest Ekso Bionics Subsidiary, Focus on Cloud Business
  • ChronoScale Amends Executive PSU Settlement to Include $1M Cash and 181K Shares
  • Applied Digital Acquires 97.5% Stake in ChronoScale, Gains Board Control

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$12.8M
Net Income
-$11.7M
Diluted EPS
-$4.91
Op. Cash Flow
-$11.8M
Free Cash Flow
-$11.99M
Gross Profit
$6.84M
Operating Income
-$13.33M
Cash & Equivalents
$1.17M
Debt / Equity
0.00×
Net Margin
-91.4%
Shares Outstanding
3.56M sh
Source: 10-K · filed 2026-04-10 · accession 0001437749-26-012069

Dilution Risk

Low risk

Filing-implied dilution signals for CHRN, detected from its recent SEC filings.

1 shelf registration

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with C →
$19.74 +0.35% today
52-week range · as of 2026-06-30 $2.91 – $28.2
Market cap
$2.82B
Volume
361.3K (1.2× avg)
3-mo avg 311.1K
Live data · 2026-08-11 07:08 UTC · Market overnight

show_chartPrice Chart

Loading chart...

feed CHRN - Latest Insights

CHRN
Jun 30, 2026, 5:14 PM EDT
Filing Type: 8-K/A
Importance Score:
8
Price at Filing: $22.66
Real-time Price: $19.74 info
Change: -$2.92 (-13%) info
Market Cap: $2.816B info
CHRN
Jun 26, 2026, 4:50 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $22.09
Real-time Price: $19.74 info
Change: -$2.35 (-11%) info
Market Cap: $2.816B info
CHRN
Jun 04, 2026, 4:15 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $23.31
Real-time Price: $19.74 info
Change: -$3.57 (-15%) info
Market Cap: $2.816B info
CHRN
May 20, 2026, 5:14 PM EDT
Filing Type: 8-K/A
Importance Score:
8
Price at Filing: $15.35
Real-time Price: $19.74 info
Change: +$4.39 (+29%) info
Market Cap: $2.816B info
CHRN
May 12, 2026, 8:30 PM EDT
Filing Type: SCHEDULE 13D
Importance Score:
10
Price at Filing: $14.38
Real-time Price: $19.74 info
Change: +$5.36 (+37%) info
Market Cap: $2.816B info